Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Immunology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLIM.2005.09.005PMID 16275091
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.

  2005influential reference
• Neurotrophic Factors and Clinical Recovery in Relapsing‐Remitting Multiple Sclerosis

  2005cited by this paper
• Management of Secondary-Progressive Multiple Sclerosis

  2004cited by this paper
• Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

  2004cited by this paper
• Current approved options for treating patients with multiple sclerosis

  2004cited by this paper
• Interferon-&bgr;-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb− and NAb+ patients

  2004cited by this paper
• Escalating immunotherapy of multiple sclerosis

  2004cited by this paper
• Immunologic factors in primary progressive multiple sclerosis

  2004cited by this paper
• Does interferon beta help in secondary progressive MS?

  2004cited by this paper
• Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ

  2003cited by this paper
• Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor

  2003cited by this paper
• Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases

  2003cited by this paper
• A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.

  2002influential reference
• Hideyo Noguchi (1876–1928)

  2002cited by this paper
• Brain-derived neurotrophic factor in patients with multiple sclerosis.

  2002cited by this paper
• MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a

  2002cited by this paper
• The influence of inhalative corticosteroids on circulating Nerve Growth Factor, Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 in allergic asthmatics

  2001cited by this paper
• Anti‐inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

  2001cited by this paper
• Immunopathology of secondary‐progressive multiple sclerosis

  2001cited by this paper
• Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System

  2000cited by this paper
• Detection of ventricular enlargement in patients at the earliest clinical stage of MS

  2000cited by this paper
• Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell costimulatory molecules B7 and CD40 on cultured rat microglia.

  1999cited by this paper
• Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS

  1999cited by this paper
• Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor.

  1998cited by this paper
• Interferon‐β Is a Potent Promoter of Nerve Growth Factor Production by Astrocytes

  1997cited by this paper
• For Personal Use. Only Reproduce with Permission from Elsevier Ltd Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: a Randomised, Double-blind, Placebo-controlled Trial

  year unknowncited by this paper

• BDNF Signaling in Glutamatergic Neurons During Long-Term Potentiation (LTP): A Spatio-Temporal Exploration of Events

  2025cites this paper
• BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients

  2025cites this paper
• The relevance of BDNF for neuroprotection and neuroplasticity in multiple sclerosis

  2024cites this paper
• Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

  2023cites this paper
• Nerve Growth Factor and Autoimmune Diseases

  2023cites this paper
• The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement

  2022cites this paper
• Ketogenic and Modified Mediterranean Diet as a Tool to Counteract Neuroinflammation in Multiple Sclerosis: Nutritional Suggestions

  2022cites this paper
• Interferon Beta-1a versus Combined Interferon Beta-1a and Oligodendrocyte-Specific FGFR1 Deletion in Experimental Autoimmune Encephalomyelitis

  2022cites this paper
• Neuroprotective Effects of Telmisartan and Nifedipine Against Cuprizone-Induced Demyelination and Behavioral Dysfunction in Mice: Roles of NF-κB and Nrf2

  2021cites this paper
• miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study

  2021cites this paper
• The Effect of IFN-β Treatment on Plasma Levels of BDNF and IL-6 in Relapsing-Remitting Multiple Sclerosis Patients

  2021cites this paper
• Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity

  2021cites this paper
• Interferon beta-1a induces expression of brain-derived neurotrophic factor in human T lymphocytes in vitro and not in vivo

  2020cites this paper
• Hydroxyfasudil alleviates demyelination through the inhibition of MOG antibody and microglia activation in cuprizone mouse model.

  2019cites this paper
• [Brain-derived neurotrophic factor in multiple sclerosis].

  2019cites this paper
• The effect of interferon-β therapy on brain-derived neurotrophic factor serum concentration in relapsing— remitting multiple sclerosis: a randomized clinical trial

  2019cites this paper
• The glial cell line-derived neurotrophic factor family in airway infectious disease

  2018cites this paper
• Immune-cell BDNF expression in treatment-naïve relapsing-remitting multiple sclerosis patients and following one year of immunomodulation therapy.

  2018cites this paper
• Autoimmune Encephalomyelitis (EAE)

  2018cites this paper
• تاثیر چهارهفته فعالیت هوازی بر نسبت سطوح سرمی عامل نکروز تومور آلفا، اینترلوکین-10 و میزان فاکتور نوروتروفیک مشتق‌ از مغز در بافت مغز موش های C57 از طریق القایExperimental Autoimmune Encephalomyelitis (EAE)

  2018cites this paper
• Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

  2017cites this paper
• Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.

  2016cites this paper
• Neuroprotection and Recovery in Multiple Sclerosis

  2016cites this paper
• Interferon beta (IFN-β) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway

  2015cites this paper
• Immune System Induction of Nerve Growth Factor in an Animal Model of Multiple Sclerosis: Implications in Re-Myelination and Myelin Repair.

  2015cites this paper
• Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS)

  2015cites this paper
• Neurotrophic factors and their effects in the treatment of multiple sclerosis

  2015cites this paper
• Brain-Derived Neurotrophic Factor Deficiency Restricts Proliferation of Oligodendrocyte Progenitors Following Cuprizone-Induced Demyelination

  2015cites this paper
• Cell-Based Delivery of Brain-Derived Neurotrophic Factor in Experimental Allergic Encephalomyelitis

  2014cites this paper
• IFN-β alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection.

  2014cites this paper
• Pharmakologie von Interferon beta-1b

  2013cites this paper
• Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination

  2013cites this paper
• Neuroprotektion durch Beta-Interferone

  2013cites this paper
• Effects of Current Medical Therapies on Reparative and Neuroprotective Functions in Multiple Sclerosis

  2013cites this paper
• Brain Derived Neurotrophic Factor is Decreased in Chronic Fatigue Syndrome and Multiple Sclerosis

  2013cites this paper
• Evaluation of interferon-beta neutralizing antibodies in individual patients with multiple sclerosis based on phospho-specific flow cytometry

  2013cites this paper
• Effect of 10-day forced treadmill training on neurotrophic factors in experimental autoimmune encephalomyelitis.

  2013cites this paper
• Comparing brain‐derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow‐derived stem cells

  2013cites this paper
• Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study

  2013cites this paper
• What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?

  2012cites this paper
• Treatment of cognitive impairment in patients with multiple sclerosis

  2012cites this paper
• Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment.

  2011cites this paper
• Levels of BDNF Impact Oligodendrocyte Lineage Cells following a Cuprizone Lesion

  2011cites this paper
• Intracerebroventricular Transplantation of Human Mesenchymal Stem Cells Induced to Secrete Neurotrophic Factors Attenuates Clinical Symptoms in a Mouse Model of Multiple Sclerosis

  2010cites this paper
• Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence

  2010cites this paper
• Interferon-β treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation.

  2010cites this paper
• The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis

  2010cites this paper
• Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

  2010cites this paper
• Interferon-β mechanisms of action in multiple sclerosis

  2010cites this paper
• Correlations between peripheral blood mononuclear cell production of BDNF, TNF‐alpha, IL‐6, IL‐10 and cognitive performances in multiple sclerosis patients

  2009cites this paper
• Protective autoimmunity in the nervous system.

  2009cites this paper
• A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.

  2009influential citation
• Increased levels of glial cell-derived neurotrophic factor in CSF of infants with SMA.

  2009cites this paper
• Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis.

  2009cites this paper
• The role of neurotrophic factors in the pathology and treatment of multiple sclerosis

  2009cites this paper
• Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing—remitting multiple sclerosis: 2-year results from the COGIMUS study

  2009cites this paper
• Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.

  2009cites this paper
• Short communication Interferon-β induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients

  2008cites this paper
• The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies

  2008cites this paper
• Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.

  2008cites this paper
• Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.

  2008cites this paper
• Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis.

  2008cites this paper
• Interferon-β regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis

  2007cites this paper
• Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.

  2007cites this paper
• Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins

  2007cites this paper
• Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression

  2007cites this paper
• The therapeutic potential of neural stem cells

  2006cites this paper
• [Neuroprotective effect of the long-term beta-interferon course in multiple sclerosis: direct and indirect mechanisms].

  2006cites this paper